Physician profile
Bilal A Choudry
NPI 1396921144
$271,049.66
in general payments reported to CMS, 2019-2025
67 companies · $54K in 2025
The $54K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $34K · 2021: $29K · 2022: $27K · 2023: $42K · 2024: $65K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Food and Beverage: $21K · Consulting Fee: $12K · Travel and Lodging: $10K · Honoraria: $8,400 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,623.50 |
| Food and Beverage | $21,482.67 |
| Consulting Fee | $12,075.00 |
| Travel and Lodging | $10,258.40 |
| Honoraria | $8,400.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,656.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $72,891.91 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Ucb, INC. | $68,841.02 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Sk Life Science, INC. | $45,868.24 | 2020-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $36,734.65 | 2022-2025 | |
| Livanova USA, INC. | $11,177.08 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Eisai INC. | $9,793.69 | 2019-2025 | |
| Aquestive Therapeutics, INC. | $7,319.68 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $3,874.33 | 2019-2022 | |
| Allergan, INC. | $2,727.65 | 2019-2022 | |
| Pfizer INC. | $1,225.09 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,220.29 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Neurelis, INC. | $1,055.23 | 2020-2025 | Valtoco |
| Lilly USA, LLC | $786.97 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Novartis Pharmaceuticals Corporation | $699.23 | 2019-2021 | |
| Amgen INC. | $642.42 | 2019-2022 |
Show all 66 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Choudry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.